Major Lipids, Apolipoproteins, and Risk of Vascular Disease

被引:0
|
作者
Di Angelantonio, Emanuele
Sarwar, Nadeem
Perry, Philip
Kaptoge, Stephen
Ray, Kausik K.
Thompson, Alexander
Wood, Angela M.
Lewington, Sarah [2 ]
Sattar, Naveed [3 ]
Packard, Chris J. [3 ]
Collins, Rory [2 ]
Thompson, Simon G. [4 ]
Danesh, John [1 ]
机构
[1] Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Emerging Risk Factors Collaborat Coordinating Ctr, Cambridge CB1 8RN, England
[2] Univ Oxford, Oxford, England
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] MRC, Biostat Unit, Cambridge CB2 2BW, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2009年 / 302卷 / 18期
基金
英国医学研究理事会;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; NONFASTING TRIGLYCERIDES; CARDIOVASCULAR-DISEASE; HDL CHOLESTEROL; ASSOCIATION; CORONARY; STROKE; PARTICIPANTS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified. Objective To assess major lipids and apolipoproteins in vascular risk. Design, Setting, and Participants Individual records were supplied on 302 430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes. Main Outcome Measures Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. Results The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C. Conclusion Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. JAMA. 2009; 302(18): 1993-2000
引用
收藏
页码:1993 / 2000
页数:8
相关论文
共 50 条
  • [31] Bioactive lipids and vascular disease
    Das, Undurti N.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2021, 75 (10) : 1528 - 1531
  • [32] LIPIDS AND APOLIPOPROTEINS IN HUMAN ARTERIES
    YLAHERTTUALA, S
    SOLAKIVI, T
    NIKKARI, T
    ANNALS OF CLINICAL RESEARCH, 1987, 19 (06): : 406 - 406
  • [33] LIPIDS, LIPOPROTEINS, APOLIPOPROTEINS, AND ATHEROSCLEROSIS
    KREISBERG, RA
    ANNALS OF INTERNAL MEDICINE, 1983, 99 (05) : 713 - 715
  • [34] LIPIDS, LIPOPROTEINS AND APOLIPOPROTEINS IN THE ELDERLY
    MATTILA, KS
    MARNIEMI, J
    MAKI, J
    JUVA, K
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1986, 46 (02): : 131 - 136
  • [35] Lipids, Apolipoproteins, Lipid-Lowering Drugs, and the Risk of Cerebral Small Vessel Disease: A Mendelian Randomization Study
    Xie, Yi
    Liu, Shuai
    Wang, Xinyue
    Huang, Hao
    Wang, Minghuan
    Qu, Wensheng
    Yu, Zhiyuan
    Wang, Wei
    Luo, Xiang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (16):
  • [36] Blood Lipids, Lipoproteins, and Apolipoproteins With Risk of Coronary Heart Disease: A Prospective Study Among Racially Diverse Populations
    Deng, Kui
    Pan, Xiong-Fei
    Voehler, Markus W.
    Cai, Qiuyin
    Cai, Hui
    Shu, Xiao-Ou
    Gupta, Deepak K.
    Lipworth, Loren
    Zheng, Wei
    Yu, Danxia
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (10):
  • [37] Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients
    Ding, Ding
    Li, Xinrui
    Qiu, Jian
    Li, Rui
    Zhang, Yuan
    Su, Dongfang
    Li, Zhongxia
    Wang, Min
    Lv, Xiaofei
    Wang, Dongliang
    Yang, Yan
    Xia, Min
    Li, Dan
    Hu, Gang
    Ling, Wenhua
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [38] SERUM-LIPIDS AND APOLIPOPROTEINS IN ACUTE AND CHRONIC LIVER-DISEASE
    MIDDELHOFF, G
    HOPF, H
    HANIKA, I
    GRETEN, H
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (02) : 24 - 24
  • [39] Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease
    Hammami, Imen
    Mafham, Marion
    Emberson, Jonathan
    Offer, Alison
    Hopewell, Jemma C.
    Armitage, Jane
    Baigent, Colin
    Parish, Sarah
    HEART, 2025,
  • [40] APOLIPOPROTEINS AND RISK OF CORONARY HEART-DISEASE
    CONNELLY, PW
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1991, 144 (10) : 1277 - 1277